Cipher Pharmaceuticals Inc (CPH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cipher Pharmaceuticals Inc (CPH) has a cash flow conversion efficiency ratio of 0.033x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$4.45 Million ≈ $3.22 Million USD) by net assets (CA$132.84 Million ≈ $96.09 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See operational self-sufficiency of Cipher Pharmaceuticals Inc to measure how many days the company can operate on defensive assets alone.
Cipher Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how Cipher Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Cipher Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cipher Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Antipa Minerals Ltd
AU:AZY
|
-0.004x |
|
Shanghai Huaming Intelligent Terminal Equipment Co Ltd
SHE:300462
|
0.029x |
|
LIBERTY LAT.AMER.A DL-01
F:1LL
|
0.434x |
|
MEDI ASSIST HEALTHCARE SERVICES LIMITED
NSE:MEDIASSIST
|
0.026x |
|
Sarana Meditama Metropolitan
JK:SAME
|
0.011x |
|
Hutchison Telecommunications (Australia) Ltd
AU:HTA
|
0.783x |
|
Digital Imaging Technology INC
KQ:110990
|
0.003x |
|
Jiangsu Fengshan Group Co Ltd
SHG:603810
|
-0.013x |
Annual Cash Flow Conversion Efficiency for Cipher Pharmaceuticals Inc (2004–2025)
The table below shows the annual cash flow conversion efficiency of Cipher Pharmaceuticals Inc from 2004 to 2025. For the full company profile with market capitalisation and key ratios, see CPH stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CA$126.01 Million ≈ $91.16 Million |
CA$30.25 Million ≈ $21.88 Million |
0.240x | +25.68% |
| 2024-12-31 | CA$102.34 Million ≈ $74.03 Million |
CA$19.55 Million ≈ $14.14 Million |
0.191x | -3.88% |
| 2023-12-31 | CA$80.52 Million ≈ $58.25 Million |
CA$16.00 Million ≈ $11.57 Million |
0.199x | +20.40% |
| 2022-12-31 | CA$64.08 Million ≈ $46.35 Million |
CA$10.57 Million ≈ $7.65 Million |
0.165x | -53.53% |
| 2021-12-31 | CA$38.90 Million ≈ $28.14 Million |
CA$13.81 Million ≈ $9.99 Million |
0.355x | -0.84% |
| 2020-12-31 | CA$32.64 Million ≈ $23.61 Million |
CA$11.69 Million ≈ $8.46 Million |
0.358x | +13.23% |
| 2019-12-31 | CA$28.01 Million ≈ $20.26 Million |
CA$8.86 Million ≈ $6.41 Million |
0.316x | -30.60% |
| 2018-12-31 | CA$24.76 Million ≈ $17.91 Million |
CA$11.28 Million ≈ $8.16 Million |
0.456x | -47.55% |
| 2017-12-31 | CA$22.94 Million ≈ $16.59 Million |
CA$19.93 Million ≈ $14.42 Million |
0.869x | +36.48% |
| 2016-12-31 | CA$18.01 Million ≈ $13.03 Million |
CA$11.47 Million ≈ $8.30 Million |
0.637x | +344.92% |
| 2015-12-31 | CA$54.26 Million ≈ $39.25 Million |
CA$7.76 Million ≈ $5.62 Million |
0.143x | +137.44% |
| 2014-12-31 | CA$6.62 Million ≈ $4.79 Million |
CA$-2.53 Million ≈ $-1.83 Million |
-0.382x | -298.20% |
| 2013-12-31 | CA$36.40 Million ≈ $26.33 Million |
CA$7.02 Million ≈ $5.08 Million |
0.193x | -65.14% |
| 2012-12-31 | CA$12.47 Million ≈ $9.02 Million |
CA$6.90 Million ≈ $4.99 Million |
0.553x | +744.04% |
| 2011-12-31 | CA$9.30 Million ≈ $6.73 Million |
CA$-799.22K ≈ $-578.14K |
-0.086x | -179.29% |
| 2010-12-31 | CA$11.47 Million ≈ $8.30 Million |
CA$1.24 Million ≈ $899.02K |
0.108x | +187.56% |
| 2009-12-31 | CA$10.47 Million ≈ $7.58 Million |
CA$-1.30 Million ≈ $-937.48K |
-0.124x | -50.64% |
| 2008-12-31 | CA$10.71 Million ≈ $7.74 Million |
CA$-879.21K ≈ $-636.01K |
-0.082x | +67.46% |
| 2007-12-31 | CA$15.83 Million ≈ $11.45 Million |
CA$-4.00 Million ≈ $-2.89 Million |
-0.252x | +58.75% |
| 2006-12-31 | CA$18.41 Million ≈ $13.32 Million |
CA$-11.27 Million ≈ $-8.15 Million |
-0.612x | +2.30% |
| 2005-12-31 | CA$19.16 Million ≈ $13.86 Million |
CA$-12.00 Million ≈ $-8.68 Million |
-0.626x | +2.30% |
| 2004-12-31 | CA$25.36 Million ≈ $18.34 Million |
CA$-16.26 Million ≈ $-11.76 Million |
-0.641x | -- |
About Cipher Pharmaceuticals Inc
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead… Read more